JP2024542235A5 - - Google Patents

Info

Publication number
JP2024542235A5
JP2024542235A5 JP2024529873A JP2024529873A JP2024542235A5 JP 2024542235 A5 JP2024542235 A5 JP 2024542235A5 JP 2024529873 A JP2024529873 A JP 2024529873A JP 2024529873 A JP2024529873 A JP 2024529873A JP 2024542235 A5 JP2024542235 A5 JP 2024542235A5
Authority
JP
Japan
Prior art keywords
cys
seq
amino acid
scfv
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542235A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/061241 external-priority patent/WO2023089587A1/en
Publication of JP2024542235A publication Critical patent/JP2024542235A/ja
Publication of JP2024542235A5 publication Critical patent/JP2024542235A5/ja
Pending legal-status Critical Current

Links

JP2024529873A 2021-11-22 2022-11-21 免疫応答のための増強された多重特異性結合剤を含む組成物 Pending JP2024542235A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163281954P 2021-11-22 2021-11-22
US63/281,954 2021-11-22
US202263322158P 2022-03-21 2022-03-21
US63/322,158 2022-03-21
US202263393750P 2022-07-29 2022-07-29
US63/393,750 2022-07-29
PCT/IB2022/061241 WO2023089587A1 (en) 2021-11-22 2022-11-21 Compositions comprising enhanced multispecific binding agents for an immune response

Publications (2)

Publication Number Publication Date
JP2024542235A JP2024542235A (ja) 2024-11-13
JP2024542235A5 true JP2024542235A5 (cg-RX-API-DMAC7.html) 2025-12-01

Family

ID=84370675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529873A Pending JP2024542235A (ja) 2021-11-22 2022-11-21 免疫応答のための増強された多重特異性結合剤を含む組成物

Country Status (9)

Country Link
US (1) US20250320304A1 (cg-RX-API-DMAC7.html)
EP (1) EP4436669A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542235A (cg-RX-API-DMAC7.html)
KR (1) KR20240111783A (cg-RX-API-DMAC7.html)
AU (1) AU2022392829A1 (cg-RX-API-DMAC7.html)
CA (1) CA3239224A1 (cg-RX-API-DMAC7.html)
IL (1) IL312968A (cg-RX-API-DMAC7.html)
MX (1) MX2024006205A (cg-RX-API-DMAC7.html)
WO (1) WO2023089587A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL326398A (en) * 2023-08-07 2026-04-01 Janssen Biotech Inc Gucy2c antibodies and uses thereof
US20250361317A1 (en) 2024-05-24 2025-11-27 Janssen Biotech, Inc. Bispecific antibody targeting emr2 (cd312) and the t-cell receptor trbv19

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
IN2014CN03887A (cg-RX-API-DMAC7.html) 2011-10-27 2015-10-16 Genmab As
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
PT2970980T (pt) 2013-03-15 2018-11-19 Janssen Biotech Inc Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes
JP6696982B2 (ja) * 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドXencor、 Inc. Cd3および腫瘍抗原に結合するヘテロ二量体抗体
CN109843926B (zh) 2016-09-30 2023-01-20 豪夫迈·罗氏有限公司 针对cd3的双特异性抗体
TW202120537A (zh) * 2019-08-15 2021-06-01 美商健生生物科技公司 用於經改善的單鏈可變片段之材料及方法

Similar Documents

Publication Publication Date Title
US20210189011A1 (en) Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
JP7600327B2 (ja) Pd-1とvegfを標的とした四価二重特異性抗体、その製造方法および用途
JP2022079549A5 (cg-RX-API-DMAC7.html)
HRP20241775T1 (hr) Bispecifična protutijela koja se specifično vežu na pd1 i lag3
JP2019533441A5 (cg-RX-API-DMAC7.html)
JP2018502050A5 (cg-RX-API-DMAC7.html)
FI3561057T3 (fi) Anti-cd3-vasta-aine ja vasta-ainetta sisältäviä molekyylejä
CN119032104A (zh) 抗血清白蛋白纳米抗体及其衍生物
JP2023139025A (ja) 二重特異性抗原結合コンストラクト
JP7826320B2 (ja) 二重または多重特異性抗体{Bi or Multi-Specific Antibody}
RU2024116415A (ru) Композиции, содержащие улучшенные мультиспецифические связывающие агенты для иммунного ответа
JP2022545368A5 (cg-RX-API-DMAC7.html)
HK40050601A (en) Dual variable region antibody-like binding proteins having cross-over binding region orientation
RU2022103028A (ru) Антитела против рецептора программируемой смерти pd-1 человека
RU2021118725A (ru) Биспецифические антитела, связывающиеся с tfr
HK1247929A1 (en) Dual variable region antibody-like binding proteins having cross-over binding region orientation
HK1247929B (en) Dual variable region antibody-like binding proteins having cross-over binding region orientation
RU2022133024A (ru) Анти-cd3 антитело и молекула, содержащая это антитело
HK1194744B (en) Dual variable region antibody-like binding proteins having cross-over binding region orientation